Na-Phenylbutyrate VAscular Trial
ConditionDiabetes
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Pennsylvania
About this trial
This study will investigate if the drug sodium phenylbutyrate (NaPB) impacts blood pressure and vascular function in healthy volunteers and in patients with diabetes.
Eligibility criteria
Qualifiers
Over 18 years of age and less than 60.
Healthy subjects will have no history of diabetes or prediabetes.
Diabetes subjects can be either insulin dependent or not.
Able to provide written consent and to comply with the procedures of the study protocol.
Disqualifiers
Age <18 or >60
Pregnant or lactating women.
Subjects with hypertension or taking any vasodilatory medications, any steroidal drugs, haloperidol, or valproic acid.
Patients with congestive heart failure, severe renal insufficiency, hepatic failure, or known sodium retention with oedema.
Trial design
Treatments tested in this trial
- Sodium Phenylbutyrate
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Pennsylvania
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov